Clinical Trials
30 trialsChemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
National Cancer Institute (NCI)
ADCC
National Cancer Institute (NCI)
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
MAESTRO HN
National Cancer Institute (NCI)
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
National Cancer Institute (NCI)
Neck Surgery in Treating Patients With Early-Stage Oral Cancer
National Cancer Institute (NCI)
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
National Cancer Institute (NCI)
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
National Cancer Institute (NCI)
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx
National Cancer Institute (NCI)
PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer
National Cancer Institute (NCI)
Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
National Cancer Institute (NCI)
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Quality-Of-Life Assessment in Patients With Head and Neck Cancer Treated With Radiation Therapy
National Cancer Institute (NCI)
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)
Computer-Assisted Scheduling of Nicotine Inhaler Use in Participants Who Plan to Stop Smoking
National Cancer Institute (NCI)
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
National Cancer Institute (NCI)
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer
National Cancer Institute (NCI)